Targeted therapies, or treatments directed towards specific biomarkers in tumor cells, have been effective in treating many patients with advanced-stage non-small cell lung cancer (NSCLC). Tumors that have the ALK protein fused with another cancer-driving protein, such as the EML4 protein, are often referred to as ALK-positive tumors. Approximately 5% of advanced-stage adenocarcinoma, a type of NSCLC, will test positive for an ALK-fusion biomarker. Treating patients with ALK-positive lung cancer with a class of drugs called tyrosine kinase inhibitors (TKIs) has been an effective approach

Brain metastases are known to occur in approximately 25% of patients diagnosed with lung cancer. This webinar dives into the details of brain metastasis in lung cancer to explore their signs and symptoms. It also includes a discussion of treatment considerations. Through this webinar, you will learn to: Understand how brain metastasis occurs Keep an eye out for signs & symptoms of brain mets Understand treatment options and management techniques This webinar was created in partnership with LUNGevity Foundation and American Brain Tumor Association with support from Novocure. Hosts: Upal Basu

Pulmonary rehab expert Debbie Koehl, MS, RRT-NPS, AE-C, FAARC, speaks to LUNGevity's Survivorship Navigator, Kristi Griffith, to explain what pulmonary rehabilitation is, explore the benefits of pulmonary rehabilitation, and gain key insights about how to obtain pulmonary rehabilitation for yourself or a loved one. The discussion is followed by an informal Q&A with other lung cancer survivors. This recording was made during one of LUNGevity Foundation's Virtual Meetups -- a free resource for the lung cancer community. See the full schedule of Virtual Meetups at lungevity.org/meetups.

In this video, nurse practitioner Lauren Welch, MSN, NP-C, AOCNP, from the Sarah Cannon Research Institute at Tennessee Oncology offers a quick review of pneumonitis - a common side effect of some lung cancer treatments. Survivors and caregivers can learn: What is pneumonitis? What causes it? How is it treated? What symptoms should we look out for?

LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director of Research, interviewed Hilary Hammell (RETpositive) and Dr. Alexandre Reuben (MD Anderson Cancer Center) about an exciting project on using the immune system to treat RET-positive lung cancer. This project is being funded by the RETpositive patient group. This interview was live on Facebook on October 18; watch the video here.

Lung cancer survivor Jill Feldman joins radiation therapy experts Drs. Drew Moghanaki and Kristin Higgins to provide an overview of radiation therapy – including discussions of when this treatment is recommended, how the treatment is administered, and which side effects are most common.

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.